1.1.99.21	pharmacology	miglitol (N-hydroxyethyl-1-deoxynojirimycin), a type of hypoglycemic drug works by competitively inhibiting alpha-glucosidase activity to control postprandial blood glucose, can be used in the treatment of type II diabetes mellitus. 6-(N-hydroxyethyl)-amino-6-deoxy-alpha-L-sorbofuranose, is a key intermediate for the synthesis of miglitol, is produced from N-2-hydroxyethyl glucamine (NHEG) by biotransformation with resting cells of Gluconobacter oxydans. Balanced co-expression of both the mSLDH and the PQQ synthases is effective for the industrial production of 6-(N-hydroxyethyl)-amino-6-deoxy-L-sorbofuranose	
1.1.99.21	pharmacology	synergistic improvement of PQQ-dependent D-sorbitol dehydrogenase activity from Gluconobacter oxydans for the biosynthesis of miglitol precursor 6-(N-hydroxyethyl)-amino-6-deoxy-alpha-L-sorbofuranose. Miglitol (N-hydroxyethyl-1-deoxynojirimycin) is a pseudomonosaccharide glucosidase inhibitor in the treatment of non-insulin-dependent mellitus	
1.1.99.21	synthesis	production of 6-amino-L-sorbose, which is an intermediate in the miglitol production and an intermediate for oral alpha-glucosidase-inhibitors	
1.1.99.21	synthesis	the most prominent industrial method of producing L-sorbose is the biotransformation of D-sorbitol to L-sorbose in Gluconobacter species or Acetobacter species. L-sorbose is an important carbohydrate that is predominantly used as a starting material in the biosynthesis of L-ascorbic acid	
1.1.99.21	synthesis	biosynthesis of miglitol intermediate 6-(N-hydroxyethyl)-amino-6-deoxy-alpha-L-sorbofuranose by an improved D-sorbitol dehydrogenase from Gluconobacter oxydans. Miglitol (N-hydroxyethyl-1-deoxynojirimycin) is a pseudomonosaccharide alpha-glucosidase inhibitor in the treatment of non-insulin-dependent mellitus